BMY Bristol-Myers Squibb Co.

$BMY $SLS $ABBV Part 4. AbbVie with Venetoclax is the current standard of care for AML induction in older patients and those with comorbidities. AbbVie knows better than anyone that Venetoclax resistance is the single biggest problem in AML right now. SLS009 directly addresses that resistance by hitting MCL1. GPS then maintains the remission that 009 restores. AbbVie watching a two asset platform emerge that could both rescue Venetoclax resistant patients and maintain them long term is an existential commercial threat to their flagship oncology asset. Acquiring SELLAS converts that threat into a Venetoclax franchise extension. ✌️🙏❤️‍🩹

$BMY $SLS Part 3. (GPS) is an immunotherapy that trains the patient's own immune system to hunt down residual cancer cells expressing the WT1 protein. GPS offers a “favorable" profile because it targets cancer cells specifically with minimal toxicity - because it is an immunotherapeutic, side effects are primarily low-grade local injection site reactions (redness/mild pain). • No Myelosuppression: Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. • Preserved Quality of Life: Patients generally do not experience the daily fatigue or GI distress associated with oral maintenance chemotherapy. While Onureg is FDA-approved for CR1 (first remission), GPS has shown compelling data both in CR1 as well as in the more difficult-to-treat CR2 (second remission) setting, where prognosis is typically dire. ✌️🙏❤️‍🩹

$BMY $SLS Part 2. BMS is sitting on Onureg, currently the only approved AML maintenance therapy but only in CR1. GPS REGAL reads out Breakthrough. GPS becomes the superior maintenance option in CR2 and the Phase 2 CR1 data suggests GPS would supercede Onureg in CR1 as well. BMS watching their AML maintenance franchise get disrupted while simultaneously holding years of nivolumab combination data showing GPS works beautifully in low burden remission settings puts them in a very uncomfortable position. The logical response is to own GPS rather than compete with it. ✌️🙏❤️‍🩹

BRISTOL MYERS SQUIBB $BMY Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $13.1B (Est. $12.74B) 🟢; +7% YoY 🔹 Gross Margin: 68.4%; -450 bps YoY 🔹 Adj. EPS: $1.35 (Est. $1.14) 🟢; -17% YoY 🔹 Growth Portfolio Revenue: $7.7B; +12% YoY FY26 Guide: 🔹 Revenue: $49.75B-$50.25B (Est. $49.89B) 🟡; from ~$49.0B-$50.0B 🔹 Adj. EPS: $6.35-$6.55 (Est. $6.49) 🟡; from $6.75-$7.00 🔹 Gross Margin: ~69%-70% 🔹 OpEx: ~$16.5B 🔹 Other Expense: ~$650M 🔹 Tax Rate: ~18% 🔹 Eliquis Growth: 20%-25% Segment Net Revenue: 🔹 Growth Portfolio: $7.7B; +12% YoY 🔹 Legacy Portfolio: $5.4B; +1% YoY Announcements: 🔹 Zenbexus: 51% reduction in risk of disease progression or death 🔹 Camzyos: FDA approved for adults and pediatric patients weighing 30 kg or more Key Updates: 🔹 Houston Campus: approximately $2.3B investment; nearly 500 jobs 🔹 RayzeBio: more than $173M Whitestown facility investment

$BMY: Bristol Myers Squibb announced promising results from a Phase 3 trial of RYZ101, an experimental cancer treatment developed by its RayzeBio subsidiary. The drug helped patients with rare digestive-system tumors live longer without their cancer getting worse, compared with standard treatments. These patients’ cancers had progressed after earlier radiation-based therapy. The study met its main goal, and safety results matched the treatment’s known profile. The FDA granted RYZ101 Orphan Drug Designation in August. BMY plans to discuss next steps toward potential FDA approval. Full results are expected at a future medical meeting. The stock is up this morning. (Source: Bristol Myers Squibb)

$BMY Impressive number here Bristol-Myers' Iza-Bren Cuts Risk Of Progression Or Death By 59% In Phase 3 Breast Cancer Study Median progression-free survival was 8.2 months vs 4.0 for chemo, and the confirmed response rate was 40.5% vs 20.2%.

$BMY Q3 net product sales rose 6% to 12.61 billion dollars even though gross product sales fell 20% to 17.97 billion dollars. Gross to net adjustments dropped from 47% to 30% of gross sales, and U.S. GTN fell from 54% to 32%, a shift the filing ties primarily to the Eliquis list price reduction in the U.S. this year. Medicaid and Medicare rebates alone fell 66% in the quarter, to 1.65 billion dollars from 4.89 billion dollars.

$BMY Follow-up: Is the cut in 2026 EPS guidance to $6.35–6.55 only a licensing-charge hit, not a weaker core business? 🏢 Bristol Myers Squibb, maker of Eliquis and Opdivo worth about $123.73B at $60.57 at 16:00 ET on October 28, 2026, follows its Oct 12 RYZ101 Phase 3 win with Q3 results that raise 2026 revenue guidance to ~$49.75–50.25B but cut non-GAAP EPS guidance to $6.35–$6.55 from $6.75–$7.00 🧾 The EPS cut, about $0.43 at the midpoint, comes from Acquired IPRD charges for licensing deals, now a $(0.60) per-share hit in guidance against $(0.02) in July 🚀 Excluding that line, the guide would be about $6.95–7.15 vs $6.77–7.02 in July; other expense guidance also eased to ~$650M from ~$700M on favorable net interest 📅 Next: Guidance excludes Acquired IPRD charges after September 30, 2026, so new licensing deals could cut it again Source: SEC 8-K + Q3 release, Oct 29, 2026

$BMY reported earnings before the open: adjusted EPS of $1.35 vs. $1.10 estimated, a beat of 22.7%. I used Stock Meadow to review the results.

$BMY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.35 down -17.18% YoY • Reported revenue of $13.07B up 7.12% YoY • Bristol Myers Squibb raised 2026 non-GAAP revenue guidance to approximately $49.75B to $50.25B and updated non-GAAP EPS guidance to $6.35 to $6.55, including -$0.6 from Acquired IPRD charges and licensing income.

$BMY | Bristol Myers Q3 2026 Earnings - Rev: $13.07B (est $12.71B) - Adj EPS: $1.35 (est $1.12) - Eliquis Rev: $4.69B (est $4.63B) - Sees FY Rev: About $49.75B To $50.25B (est $49.88B; prev About $49B To $50B) - Sees FY Adj EPS: $6.35 To $6.55 (est $6.36; prev $6.75 To $7)

$BMY $BKYI Natural gas M&A is heating up. EQT announced an all-stock acquisition of Range Resources, creating a U.S. producer with pro forma enterprise value above $50B, including debt. The offer implies a roughly 20.6% premium for Range shareholders.

$BMY reports earnings tomorrow before the open. I’m bullish heading into the report: BMY has beaten EPS estimates in 8 of its last 8 reports, according to Stock Meadow.

$BMY Bristol Myers reports Thursday before the open. Zacks consensus is 1.28 dollars a share, down 21.5% from a year ago, on 12.56 billion dollars of revenue, up 2.8%. The EPS estimate has been revised 0.65% lower in the last 30 days, and the Zacks Earnings ESP sits at -15.06%. Q2 went the other way though. The company posted 2.04 dollars vs 1.59 expected, a 28.3% surprise, and it has beaten the EPS consensus four quarters in a row. Full-year EPS guidance is 6.75 to 7.00 dollars.

$BMY Very encouraging! Bristol Myers Squibb Co. (BMY) stock is climbing in pre-market trading due to broader healthcare sector momentum, positive updates surrounding its growth-led pipeline portfolio, and technical buying interest ahead of its upcoming Q3 earnings report scheduled for October 29.

🟢 $BMY 61C Oct 30 💰 $214,200 premium 💵 $0/contract 📊 2x Vol/OI 📍 Spot $61.55 💰 Large premium 🌊 Dark Flow | Options Flow

$BMY Back in with a full position Lost the gap open anchored vwap of $60.60 from last Thursday, went back and filled the gap and bounced off the rising 5 DMA for my entry. This AVWAP is the volume weighted average price paid for every share since it gap opened Oct 15 and hit a high $62.25 before losing it.

$BMY pipeline moving nicely. Camzyos grew by 60% to approximately $416 million, Breyanzi increased by 41% to approximately $484 million, Reblozyl rose by 29% to approximately $735 million, and Opdualag reached $349 million after growing by 23%.

$BMY BMY is having a good day while much of the market is not. Shares near 59.34, up about 4.66 percent. My read is a defensive rotation. Hot September inflation hit growth stocks today, and money moved toward steadier names. Discount retailers were higher too, and BMY is a low beta pharma with a 4 percent dividend yield. The backdrop is mixed. The Q2 report in July beat estimates and raised full year guidance, with adjusted EPS of 2.04 against about 1.59 expected. But the stock still sits well below its 52 week high of 68.64, with investors worried about replacing revenue as Eliquis and Opdivo lose patent protection. Next earnings are expected around October 29. Follow me if you want more on the pharma names.

Big pharma was supposed to be the safe trade. $BMY closed Monday at 57.58, its lowest since July, on about twice normal volume, and it sliced under its 200-day near 59.55. If it can't get back above that 200-day, I'm staying away.